Journals / Endoüroloji Bülteni / 2021 / Cilt: 13 - Sayı: 1

Urosepsis after endoscopic urinary system stone treatment: factors increasing risk

Endoskopik üriner sistem taş tedavisi sonrası ürosepsis: riski artıran faktörler

Pages
10–16
Publication Date
2021-01-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Findings to be obtained with high patient numbers may decrease the cost and morbidity rates created by urosepsis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Urinary system stones are an increasingly common disease that creates serious financial burden on the health system.
📊
Key Findings & Data:In this study, we examined the incidence of urosepsis in patients applied endoscopic stone treatment and the factors that increase it.
💡
Conclusion & Impact:Findings to be obtained with high patient numbers may decrease the cost and morbidity rates created by urosepsis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:ürosepsis · endoüroloji · antibiyotik

Abstract

Objective: Urinary system stones are an increasingly common disease that creates serious financial burden on the health system. Urinary infections are substantial after endoscopic treatment of urolithiasis. In this study, we examined the incidence of urosepsis in patients applied endoscopic stone treatment and the factors that increase it. Thus, we aimed to contribute to the discussion on measures to be taken to prevent urosepsis in patients. Material and Methods: Patients who underwent endoscopic stone treatment for kidney or ureteral stones were included in the study. The two groups, which were divided into those with and without sepsis, were compared with each other in terms of age, gender, comorbidity, and residual stones. Results: The total number of patients included in the study was 561. The median age of the patients included in the study was 39 (18-77). Sepsis findings were observed in 12 (4.2%), 31 (14.2%) and 9 (16.7%) patients, respectively, in patients grouped according to the age range of 18-40, 41-60 and 61-80 years. There was a significant difference between these groups in terms of the incidence of sepsis (p <0.001). While 39 (25.3%) patients had sepsis in the patient group with comorbidity, 13 (3.2%) patients had sepsis in the patient group without comorbidity. A statistically significant difference was found between the two groups in terms of the rates of sepsis (p <0.001). Conclusion: Recognizing the factors that facilitate postoperative urosepsis is important for effective prophylaxis and effective antibiotherapy in treatment. Findings to be obtained with high patient numbers may decrease the cost and morbidity rates created by urosepsis.

Özet

Amaç: Üriner sistem taşları sıklığı giderek artan, sağlık sistemi üzerine ciddi mali yük oluşturan bir hastalıktır. Ürolitiyazisin endoskopik tedavisi sonrasında üriner enfeksiyonlar azımsanmayacak düzeydedir. Bu çalışmada endoskopik taş tedavisi alan hastalarda ürosepsis görülme insidansı ve bunu arttıran faktörleri inceledik. Böylece hastalarda ürosepsisi engellemeye yönelik alınacak tedbirlerle ilgili tartışamaya katkı sağlamayı amaçladık. Gereç ve Yöntemler: Böbrek veya üreter taşı nedeni ile endoskopik taş tedavisi yapılan hastalar çalışmaya dahil edildi. Sepsis geçiren ve geçirmeyen olarak ayrılan iki grup birbiri ile yaş, cinsiyet, komorbidite, rezidü taş açısından birbiri ile kıyaslandı. Bulgular: Çalışmaya dahil edilen toplam hasta sayısı 561’di. Çalışmaya dahil edilen hastaların median yaşı 39 (18-77)’ti. 18-40, 41-60 ve 61-80 yaş aralıklarına göre gruplanan hastalarda sırasıyla 12 (%4.2), 31 (%14.2) ve 9 (%16.7) hastada sepsis bulguları görüldü. Bu gruplar arasında sepsis görülme oranları açısından anlamlı fark vardı (p<0,001). Komorbiditesi olan hasta grubunda 39 (%25.3) hastada sepsis görülürken, komorbiditesi olmayan hasta grubunda 13 (%3.2) hastada sepsis görüldü. İki grup arasında sepsis görülme oranları açısından istatistiksel olarak anlamlı fark bulundu (p<0,001). Sonuç: Postoperatif ürosepsisi kolaylaştırıcı etmenlerin bilinmesi, etkili proflaksi ve tedavide etkin antibiyoterapi açısından önemlidir. Yüksek hasta sayıları ile elde edilecek bulgular ürosepsisin yarattığı maliyet ve morbidite oranlarını düşürebilir.

🔖

Cite This Article

BULUT, D., SAYAR, M. S., BULUT, E. C., BİTKİN, A., BIÇAKLIOĞLU, F., ÇETİN, S., KOPARAL, M., ERTAŞ, K. (2021). Urosepsis after endoscopic urinary system stone treatment: factors increasing risk. Endoüroloji Bülteni, Cilt: 13 - Sayı: 1, 10–16. https://ajindex.com/articles/754129

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Miller, N.L. & Lingeman, J.E. Management of kidney stones. Bmj 334, 468-472 (2007)
  2. Pearle, M.S., Calhoun, E.A., Curhan, G.C. & Project, U.D.o.A. Urologic diseases in America project: urolithiasis. The Journal of urology 173, 848-857 (2005)
  3. De La Rosette, J., et al. The clinical research office of the endourological society ureteroscopy global study: indications, complications, and outcomes in 11,885 patients. Journal of Endourology 28, 131-139 (2014)
  4. Romero, V., Akpinar, H. & Assimos, D.G. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Reviews in urology 12, e86 (2010)
  5. Soucie, J.M., Thun, M.J., Coates, R.J., McClellan, W. & Austin, H. Demographic and geographic variability of kidney stones in the United States. Kidney international 46, 893-899 (1994)
  6. Sánchez-Martín, F. & Martínez-Rodríguez, R. Incidence and prevalence of published studies about urolithiasis in Spain. A review. Actas Urológicas Españolas 31, 511-520 (2007)
  7. Wright, A.E., Rukin, N.J. & Somani, B.K. Ureteroscopy and stones: Current status and future expectations. World journal of nephrology 3, 243 (2014)
  8. Giusti, G., et al. Sky is no limit for ureteroscopy: extending the indications and special circumstances. World journal of urology 33, 257-273 (2015)
  9. Fall, B., Mouracade, P., Bergerat, S. & Saussine, C. Flexible ureteroscopy and laser lithotripsy for kidney and ureter stone: indications, morbidity and outcome. Progres en urologie: journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 24, 771 (2014)
  10. Cindolo, L., et al. Mortality and flexible ureteroscopy: analysis of six cases. World journal of urology 34, 305-310 (2016)
  11. Turk, C., et al. European Association of Urology Guidelines on Urolithiasis, 2012. Available via www. uroweb. org/gls/pdf/20_Urolithiasis_LR% 20March 202012(2013)
  12. Somani, B., et al. Complications associated with ureterorenoscopy (URS) related to treatment of urolithiasis: the Clinical Research Office of Endourological Society URS Global study. World journal of urology 35, 675-681 (2017)
  13. Berardinelli, F., et al. A prospective multicenter European study on flexible ureterorenoscopy for the management of renal stone. International braz j urol 42, 479-486 (2016)
  14. Baş, O., et al. Factors affecting complication rates of retrograde flexible ureterorenoscopy: analysis of 1571 procedures—a single-center experience. World journal of urology 35, 819-826 (2017).